T
Todd E. DeFor
Researcher at University of Minnesota
Publications - 297
Citations - 19625
Todd E. DeFor is an academic researcher from University of Minnesota. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 64, co-authored 288 publications receiving 17856 citations. Previous affiliations of Todd E. DeFor include City of Hope National Medical Center.
Papers
More filters
Journal ArticleDOI
Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems.
Margaret L. MacMillan,Daniel J. Weisdorf,John E. Wagner,Todd E. DeFor,Linda J. Burns,Norma K.C. Ramsay,Stella M. Davies,Bruce R. Blazar +7 more
TL;DR: The data suggest that steroids provide an active but inadequate therapy for acute GVHD, especially with higher grade GV HD, and that more effective prophylaxis and therapy is needed for mismatched unrelated donor recipients and for those with severe GVhd.
Journal ArticleDOI
Umbilical cord blood–derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect
Claudio G. Brunstein,Jeffrey S. Miller,David H. McKenna,Keli L. Hippen,Todd E. DeFor,Darin Sumstad,Julie M. Curtsinger,Michael R. Verneris,Margaret L. MacMillan,Bruce L. Levine,James L. Riley,Carl H. June,Chap T. Le,Daniel J. Weisdorf,Philip B. McGlave,Bruce R. Blazar,John E. Wagner +16 more
TL;DR: Hematopoietic recovery and chimerism, cumulative density of infections, nonrelapse mortality, relapse, and disease-free survival were similar in the Treg recipients and controls.
Journal ArticleDOI
Clearance of Acute Myeloid Leukemia by Haploidentical Natural Killer Cells Is Improved Using IL-2 Diphtheria Toxin Fusion Protein
Veronika Bachanova,Sarah Cooley,Todd E. DeFor,Michael R. Verneris,Bin Zhang,David H. McKenna,Julie M. Curtsinger,Angela Panoskaltsis-Mortari,Dixie Lewis,Keli L. Hippen,Philip B. McGlave,Daniel J. Weisdorf,Bruce R. Blazar,Jeffrey S. Miller +13 more
TL;DR: The need to optimize the in vivo cytokine milieu where adoptively transferred NK cells compete with other lymphocytes to improve clinical efficacy in patients with refractory AML is supported.
Journal ArticleDOI
Cerebral X-linked adrenoleukodystrophy: the international hematopoietic cell transplantation experience from 1982 to 1999.
Charles Peters,Lawrence R. Charnas,Ye Tan,Richard S. Ziegler,Elsa Shapiro,Todd E. DeFor,Satkiran S. Grewal,Paul J. Orchard,S Abel,Anne I. Goldman,Norma K.C. Ramsay,Kathryn E. Dusenbery,Daniel J. Loes,Lawrence A. Lockman,Shunichi Kato,Patrick R. Aubourg,Hugo W. Moser,William Krivit +17 more
TL;DR: It is concluded that boys with early-stage disease benefit from HCT, whereas boys with advanced disease may be candidates for experimental therapies.
Journal ArticleDOI
Phase I/II Trial of StemRegenin-1 Expanded Umbilical Cord Blood Hematopoietic Stem Cells Supports Testing as a Stand-Alone Graft.
John E. Wagner,Claudio G. Brunstein,Anthony E. Boitano,Todd E. DeFor,David H. McKenna,Darin Sumstad,Bruce R. Blazar,Jakub Tolar,Chap T. Le,Julie Jones,Michael P. Cooke,Conrad C. Bleul +11 more
TL;DR: In this paper, the authors evaluated the feasibility and safety of StemRegenin-1 (SR-1), an aryl hydrocarbon receptor antagonist that expands CD34+ cells, by placing one of the two units in expansion culture.